Pfizer Posts $2.38 Billion Q3 Loss Amid Sharp Drop in Covid Vaccine and Paxlovid Revenue

Weakening demand for Covid products prompts a $3.5 billion cost-cutting plan, while sales of non-Covid drugs see a 10% growth despite Q3 losses.